<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: C-<z:chebi fb="7" ids="16670">peptide</z:chebi>, a cleavage product of insulin, exerts biological effects in patients with type 1 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, but its role in type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> is controversial </plain></SENT>
<SENT sid="1" pm="."><plain>Our aim was to examine the associations between fasting C-<z:chebi fb="7" ids="16670">peptide</z:chebi> levels and <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality, specific-cause mortality and the incidence of <z:hpo ids='HP_0011010'>chronic</z:hpo> complications in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN: Retrospective cohort study with a median follow-up of 14 years </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: A representative cohort of 2113 patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and a subgroup of 931 individuals from this cohort without <z:hpo ids='HP_0011010'>chronic</z:hpo> complications at baseline from a diabetic clinic were studied </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Patients with higher C-<z:chebi fb="7" ids="16670">peptide</z:chebi> levels had higher baseline BMI and <z:chebi fb="0" ids="17855">triglyceride</z:chebi> and lower <z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> values </plain></SENT>
<SENT sid="5" pm="."><plain>During the follow-up, 46.1% of the patients died </plain></SENT>
<SENT sid="6" pm="."><plain>In a Cox proportional hazard model, after multiple adjustments, no significant association was found between the C-<z:chebi fb="7" ids="16670">peptide</z:chebi> tertiles and <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality or mortality due to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, <z:mp ids='MP_0002055'>diabetes</z:mp> or <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>In the subgroup of 931 patients without <z:hpo ids='HP_0011010'>chronic</z:hpo> complications at baseline, the incidence of microvascular complications decreased from the first to the third C-<z:chebi fb="7" ids="16670">peptide</z:chebi> level tertile, while the incidence of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> did not differ </plain></SENT>
<SENT sid="8" pm="."><plain>The risks for incident <z:hpo ids='HP_0000488'>retinopathy</z:hpo> (hazard ratio (HR)=0.33; 95% confidence interval (CI) 0.23-0.47), <z:hpo ids='HP_0000112'>nephropathy</z:hpo> (HR=0.27; 95% CI 0.18-0.38) and <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> (HR=0.39; 95% CI 0.25-0.61) were negatively associated with the highest C-<z:chebi fb="7" ids="16670">peptide</z:chebi> tertile, after adjusting for multiple confounders </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Higher baseline C-<z:chebi fb="7" ids="16670">peptide</z:chebi> levels were associated with a reduced risk of incident microvascular complications but imparted no survival benefit to patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
</text></document>